Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Accumulated Expenses (2018 - 2024)

Historic Accumulated Expenses for Zevra Therapeutics (ZVRA) over the last 9 years, with Q4 2024 value amounting to $6.1 million.

  • Zevra Therapeutics' Accumulated Expenses fell 4259.21% to $6.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.1 million, marking a year-over-year decrease of 4259.21%. This contributed to the annual value of $6.1 million for FY2024, which is 4259.21% down from last year.
  • Per Zevra Therapeutics' latest filing, its Accumulated Expenses stood at $6.1 million for Q4 2024, which was down 4259.21% from $10.7 million recorded in Q4 2023.
  • In the past 5 years, Zevra Therapeutics' Accumulated Expenses registered a high of $10.7 million during Q4 2023, and its lowest value of $1.1 million during Q4 2021.
  • For the 5-year period, Zevra Therapeutics' Accumulated Expenses averaged around $4.2 million, with its median value being $1.7 million (2022).
  • In the last 5 years, Zevra Therapeutics' Accumulated Expenses surged by 53783.62% in 2023 and then tumbled by 4259.21% in 2024.
  • Zevra Therapeutics' Accumulated Expenses (Quarter) stood at $1.3 million in 2020, then dropped by 18.86% to $1.1 million in 2021, then soared by 58.73% to $1.7 million in 2022, then skyrocketed by 537.84% to $10.7 million in 2023, then plummeted by 42.59% to $6.1 million in 2024.
  • Its Accumulated Expenses was $6.1 million in Q4 2024, compared to $10.7 million in Q4 2023 and $1.7 million in Q4 2022.